In fact, knocking-down or pharmacological inhibition of TMEM16A/ANO1 in tumor cells inhibited their proliferation by reducing EGFR activation and its downstream signaling pathways (reviewed in [58]). This evidence concerns the gene EGFR and neoplasm.